Print Page   |   Contact Us   |   Sign In   |   Join
News & Press: Industry Events

Quorum Innovations to Participate In Human Microbiome R&D And Business Collaboration Panel

Monday, August 29, 2016   (0 Comments)
Share |


Dirk Henson


(941) 951-0126


(770) 633-6387




August 29, 2016

Quorum Innovations to Participate In Human Microbiome R&D And Business Collaboration Panel

Probiomic Therapeutics™ for Eczema, Atopic Dermatitis, Eosinophilic Esophagitis (EoE), Metabolic Disorders


Sarasota, FL, August 29, 2016– Quorum Innovations has been invited to participate on a human microbiome panel discussion at the Human Microbiome R&D and Business Collaboration Forum in LaJolla, CA on October 3rd-4th, 2016.

The World Economic Forum named human microbiome therapeutics one of the top 10 emerging technologies of 2014. The field of microbiome therapeutics represents a novel way to develop new treatments for serious diseases, as well as a new scientifically backed means to maintain health and meet increasing consumer demand for natural or “green” products.  The global microbiome therapeutics market is expected to grow to $1.2 trillion by 2016.

Dr. Nicholas Monsul - CEO and Dr. Eva Berkes – Chief Scientific Officer (Founders of Quorum Innovations) will provide information on Quorum Innovation’s Probiomic Therapeutics™. Quorum Innovations has successfully isolated LfQi6 from the human host which demonstrates novel bimodal biofilm modulation with the ability to help restore a rebalanced human microbiome. Quorum Innovation’s Probiomic Therapeutics™ inhibit and detach pathogenic biofilm while enhancing commensal resident biofilm, reducing inflammation, promoting innate immune defense by stimulating production of anti-microbial peptides. Also helping to restore impaired barriers by upregulating the expression of an essential homeostatic barrier protein, filaggrin, in human tissues.

“The Human Microbiome can be thought of as the most influential organ system within the human body.  And yet, as scientists we are only beginning to understand the molecular mechanisms by which the microbiome communicates with its symbiont host, the human.  And, as physicians, we have begun to understand how we evaluate our health and disease through the microscope of the microbiome.  As a biotech company, Quorum is at the forefront of merging the science and clinical medicine, developing microbiome therapeutics that can reinvent and reinvigorate the way medicine is delivered.”     

Emerging research on various types of skin inflammation indicate direct links to many clinical conditions and a dysbiotic or abnormal skin microbiome.  Inflamed skin can lead to dysfunction and microbiome compromise and can lead to conditions such as atopic dermatitis, psoriasis, acne and rosacea.  This has led the pharmaceutical and personal care industries to seek better ways to prevent and address skin inflammation and chronic inflammatory disorders.

Quorum’s human microbiome Probiomics™, have demonstrated proof of concept in ex-vivo, in-vitro, and initial human clinical testing.  Pre-clinical and clinical models show that these bio-extracts modulate the innate immune system by rebalancing the microbiome to: 1) reduce skin inflammation as measured by IL-1a levels, 2) enhance the diversity of the protective commensal population, 3) disperse and facilitate the kill of pathogenic biofilms such as MRSA and Pseudomonas, 4) prevent formation of new pathogenic biofilms, and 5) up-regulate filaggrin. Because Quorum’s Probiomic™ technology is effective topically, it offers broad therapeutic value with minimal systemic exposure.

Founded in 2011, Quorum Innovations, LLC (“Quorum”) is a biopharmaceutical company developing first-in-class immuno-modulators for chronic medical conditions. 


# # #

If you would like more information about this topic, please contact Dirk Henson at (941) 951-0126 or email at

BioFlorida, Inc. | 901 NW 35th Street | Boca Raton, FL 33431
(P) 561-653-3839 (F) 561-653-3840
Membership Management Software Powered by®  ::  Legal